| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Nuwellis, Inc.$3.04
+0.26 (+9.03%)
D 31Pipeline Score MedTech · Clinical
Market Cap
2.81 M
EPS
-64.11
P/E Ratio
-
Value Trade
268.50 K
SEC Financials
Q1 2026Dilution Risk
Revenue
2.40 M
R&D Expenses
1.73 M
Operating CF
-3.11 M
Total Assets
6.96 M
Total Liabilities
4.29 M
Equity
2.66 M
D/E Ratio
12,345
1.94 %
Week
-11.76 %
1 Month
-42.62 %
3 Month
-50.24 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
2.08 M
Monthly Burn
1.04 M
Runway
0.4 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
119.33 K
52 Week Range
0.90 - 40.07
% held by Insiders
1.41 %
% held by Institutions
2.28 %
Enterprise Value
1.00 M
Total Shares
1.87 M
Short %
4.95 %
Float Shares
1.54 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D31
Pipeline Score $2M
Pipeline ValueValuation Signal
1
Drugs Scored0.6x
rNPV / MCap Top 38%
Micro Cap (rank 566 of 911)
Percentile RankNuwellis, Inc. faces pipeline headwinds (31/100), with $2.5B risk-adjusted pipeline value, led by Stepped pharmacologic care in Heart Failure (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stepped pharmacologic care Small molecule | Heart Failure | Phase 3 | NCT00608491 | 48% | $2.5B | COMPLETED | 188 | - | - | Jun 1, 2012 | - | Jun 24, 2013 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NUWE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NUWE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NUWESource: Nuwellis, Inc.
Nuwellis, Inc. has announced the appointment of Mike McCormick as the new Chief Executive Officer, effective June 30, 2026, succeeding John Erb, who will remain as Chairman of the Board. McCormick brings over three decades of experience in the medical technology sector, and his leadership is anticipated to drive the company’s expansion in precision fluid management for cardiorenal care. The transition aims to leverage McCormick’s commercial expertise and strategic vision to enhance the company’s product pipeline and overall market position.
Read more →NUWENuwellis, Inc. Announces First Quarter 2026 Financial Results MINNEAPOLIS
Nuwellis, Inc. reported its first-quarter 2026 financial results, showcasing a revenue increase of 26% year-over-year, reaching $2.4 million. The company improved its gross margin to 70.1%, supported by enhanced pricing strategies and product mix. However, operating expenses rose significantly, leading to a net loss of approximately $4.3 million. Leadership emphasized the positive effects of a strategic reset initiated in 2025, aimed at focusing on key clinical areas and driving disciplined execution.
Read more →NUWENuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results MINNEAPOLIS
Nuwellis, Inc. has reported its financial results for the fourth quarter and full year ended December 31, 2025. The fourth quarter saw a revenue increase of 4% year-over-year, with a notable improvement in gross margins. However, the company experienced a 5% decline in total revenue for the full year, despite growth in specific areas such as Heart Failure and Pediatrics. Moving into 2026, Nuwellis plans to integrate its recent acquisition of Rendiatech and focus on advancing its product offerings within the cardiorenal continuum.
Read more →NUWEMinneapolis, MN
Nuwellis, Inc. has appointed David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. These appointments are aimed at enhancing the board's expertise, particularly in capital markets and medical device leadership. John Erb, the company's CEO, highlighted the importance of their combined experience for executing the company's strategic priorities. Both new board members bring extensive backgrounds in healthcare and corporate development, which are expected to contribute positively to Nuwellis's goals.
Read more →NUWE▲ +8.5%on this news
Nuwellis Announces $5 Million Private Placement and Warrant Inducement Transaction, Priced At-The-Market MINNEAPOLIS
Nuwellis, Inc. has announced a $5 million private placement and warrant inducement agreement, aimed at enhancing its capital resources. The agreement involves the sale of 994,537 shares of common stock and warrants, with an effective offering price of $3.09 per share. Additionally, Nuwellis will allow a reduction in the exercise price of existing warrants, encouraging immediate investor activity. The completion of these transactions is expected to close around January 30, 2026, contingent on standard closing conditions.
Read more →NUWENuwellis Reports Third Quarter 2025 Results and Continued Operational Momentum Company delivers steady performance and achieves key milestones across critical care, pediatrics, and hospital-based outpatient therapy MINNE
Nuwellis, Inc. reported its financial results for the third quarter of 2025, demonstrating operational momentum in various therapeutic areas. The company experienced a sequential revenue growth of 29%, bolstered by increased utilization of its products. While total revenue decreased from the previous year, management remains optimistic about the launch of new therapies and their growing focus on the U.S. market. However, rising operating expenses present potential challenges in maintaining profitability.
Read more →NUWENuwellis, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights Minneapolis, MN
Nuwellis, Inc. reported its financial results for the second quarter of 2025, highlighting a revenue decline to $1.7 million compared to $2.2 million the previous year. This decrease was attributed mainly to an industry-wide sterilization vendor issue that caused product backorder disruptions. Despite challenges, the company is strategically realigning its focus towards pediatric and cardiac surgery, and remains debt-free with $4.5 million in cash. Nuwellis aims to bolster its operational discipline and improve patient care as it enters the latter half of the year.
Read more →NUWENuwellis, Inc. Announces First Quarter 2025 Financial Results and Business Highlights Minneapolis, MN
Nuwellis, Inc. has reported its financial results for the first quarter of 2025, showing a 3% increase in revenue compared to the same quarter in 2024, reaching $1.9 million. The company recognizes advancements in its Aquadex therapy adoption due to improved reimbursement rates and performance in pediatric services. While the operating loss has improved to $3.1 million, net losses remain high at $3.0 million. The overall financial health appears cautiously optimistic as the company continues to navigate market opportunities.
Read more →NUWEInvestor Presentation April 2025 Making Aquadex the Standard of Care for Fluid Management Aquadex SmartFlow is a registered trademarks of Nuwellis, Inc. Aquadex is a trademark of Nuwellis, Inc. Safe Harbor Statement Fina
Nuwellis, Inc. plans to make Aquadex the standard of care for fluid management, emphasizing its strategic focus on critical care and pediatrics. The company highlights a significant increase in outpatient reimbursement rates, which enhances the financial viability of Aquadex treatments and aims to reduce hospital readmissions. Nuwellis is nearing critical milestones in its REVERSE-HF trial, which seeks to validate the effectiveness of Aquadex therapy compared to traditional IV loop diuretics in heart failure management. The company's focused growth strategy aims to expand its market presence and improve patient care standards.
Read more →NUWENuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results Minneapolis, MN
Nuwellis, Inc. recently reported its financial results for Q4 2024, revealing a 9% decrease in revenue to $2.3 million. However, the company experienced significant growth in consumables utilization and revenue in its Critical Care segment, indicating positive market trends. The overall operating loss improved due to reduced operating expenses and a one-time gain from a contract termination. The company remains optimistic about 2025, anticipating expansion due to improved awareness and favorable reimbursement changes.
Read more →NUWENuwellis Regains Compliance with Nasdaq Listing Requirements MINNEAPOLIS - Dec. 19, 2 024 - Nuwellis, Inc. (Nasd aq: NUWE) (the "Company" or "Nuwellis"), today announced that the Company received formal written notice fr
Nuwellis, Inc. announced that it has regained compliance with Nasdaq's listing requirements for minimum bid price and stockholders' equity. The company improved its financial standing through equity raises and restructuring liabilities. As a result, Nuwellis will continue to trade on Nasdaq under the symbol "NUWE". Additionally, a mandatory panel monitor will oversee the company for a year from the date of compliance confirmation.
Read more →NUWENuwellis, Inc. Announces Third Quarter 2024 Financial Results and Recent Highlights Minneapolis, MN
Nuwellis, Inc. announced its financial results for the third quarter of 2024, reporting a revenue of $2.4 million, a slight decline from the previous year. Despite this, the company highlighted significant growth in the Pediatric customer category and a major reimbursement increase from CMS that will expand its market potential effective January 2025. The gross margin improved to 70%, showing efficient operational management. However, a decrease in revenue and R&D expenses raises some concern about future growth and innovation.
Read more →NUWENuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds MINNEAPOLIS, November 5 , 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) ("Nuwellis" or the "Company"), a commercial-stage medical device
Nuwellis, Inc. has announced the immediate exercise of certain outstanding warrants, generating approximately $5.1 million in gross proceeds. The exercise of warrants allows for the purchase of common stock at $2.10 per share, along with the issuance of new Series I and Series II warrants at an exercise price of $1.94. This move supports the company’s focus on advancing its Aquadex SmartFlow system for treating patients suffering from fluid overload. The company plans to file a registration statement with the SEC regarding the resale of shares stemming from the new warrants.
Read more →NUWENuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules MINNEAPOLIS
Nuwellis, Inc. has announced a registered direct offering priced at-the-market under Nasdaq rules, aiming to raise approximately $916,000. The company will sell 496,901 shares at a price of $1.8450 per share, alongside warrants for the same number of shares with a lower exercise price. The proceeds are intended for working capital and general corporate purposes. The transaction is expected to close on or about August 26, 2024, subject to customary conditions. This offering reflects the company's ongoing strategy to support its operations and commercialization efforts in addressing fluid overload in patients.
Read more →NUWENuwellis, Inc. Announces Second Quarter 2024 Financial Results Minneapolis, MN
Nuwellis, Inc. reported its financial results for the second quarter of 2024, showing a 6% increase in revenue to $2.2 million, mainly due to growth in consumables usage in Critical Care and Heart Failure. The gross margin improved to 67.2%, reflecting manufacturing efficiencies. Though the company has expanded its Pediatric product offerings, it observed a decline in Pediatric utilization by 25%. Despite these advancements, Nuwellis recorded a higher net loss of $7.7 million compared to the prior year.
Read more →NUWENuwellis Announces Pricing of $2.0 Million Offering Priced At-The-Market Under Nasdaq Rules MINNEAPOLIS
Nuwellis, Inc. has announced the pricing of a $2.0 million public offering under Nasdaq rules. The offering involves the sale of 469,340 shares of common stock at a price of $4.24 per share, along with warrants for an additional purchase of shares. The transaction is expected to close on or about July 25, 2024, and the funds will primarily be used for working capital and corporate objectives. Roth Capital Partners is acting as the exclusive placement agent for this offering.
Read more →NUWEJuly 2024 Investor Presentation Aquadex FlexFlow and Aquadex SmartFlow are registered trademarks of Nuwellis, Inc. Aquadex is a trademark of Nuwellis, Inc. Safe Harbor Statement Financial and Statistical DataThis present
Nuwellis, Inc. delivered an investor presentation highlighting their Aquadex FlexFlow and SmartFlow systems aimed at addressing fluid overload in patients. The presentation outlined the significant public health challenges, particularly for heart failure patients, noting that fluid overload contributes to high hospitalization rates and costs. It also emphasized the limitations of current standard care with diuretics, suggesting a need for innovative solutions. Risks mentioned include uncertainty in market performance and potential fund-raising challenges.
Read more →NUWENuwellis Marks First Commercial Sale of QUELIMMUNE Therapy to Cincinnati Children's MINNEAPOLIS
Nuwellis, Inc. has reported its first commercial sale of QUELIMMUNE therapy to Cincinnati Children's Hospital, marking a significant step in pediatric critical care. This novel treatment, which targets children with uncontrolled inflammatory responses, offers a promising 77% survival rate for patients suffering from acute kidney injury due to sepsis. The therapy is now available through a Humanitarian Device Exemption granted by the FDA, emphasizing Nuwellis' commitment to improving outcomes in pediatric care. With the integration of QUELIMMUNE into treatment options, healthcare professionals express optimism for its potential impact on critically ill patients.
Read more →NUWENuwellis Announces Reverse Stock Split MINNEAPOLIS
Nuwellis, Inc. has announced a 1-for-35 reverse stock split of its common stock, effective June 27, 2024. This decision follows shareholder approval at the annual meeting held on June 6, 2024, where the company's board was granted the discretion for the split ratio. Post-split, every thirty-five shares will convert into one share, with the total authorized shares remaining at 100 million. The company's stock will continue trading on the Nasdaq under the symbol 'NUWE'.
Read more →NUWENuwellis and DaVita Extend Supply and Collaboration Agreement Pilot Phase Pilot Collaboration for Aquadex Ultrafiltration Therapy for Adult Patients with Congestive Heart Failure is extended to
Nuwellis, Inc. has extended its pilot collaboration with DaVita Inc. for the Aquadex ultrafiltration therapy aimed at adult patients with congestive heart failure until August 31, 2024. This collaboration allows DaVita to further evaluate the ultrafiltration therapy in high-need patients. At the pilot's conclusion, there's a possibility for a long-term supply agreement lasting up to 10 years, underscoring both companies' commitment to enhancing patient care. The Aquadex SmartFlow system aims to address fluid overload, with further commercial potential hinted. However, future market success remains contingent on overcoming various risks.
Read more →NUWENuwellis, Inc. Announces First Quarter 2024 Financial Results Minneapolis, MN
Nuwellis, Inc. reported its financial results for the first quarter of 2024, highlighting a modest revenue increase of 2% driven by growing demand for its consumables. The company's gross margin also improved, positively impacting its financial health. However, a net loss of $3.8 million indicates ongoing financial challenges, despite the overall positive trend in certain metrics. The reduction in operating expenses reflects successful cost control measures undertaken in previous quarters.
Read more →NUWENuwellis Announces Pricing of $2.7 Million Public Offering MINNEAPOLIS
Nuwellis, Inc. has announced the pricing of a public offering of 11,250,000 shares of its common stock at a price of $0.24 per share, which is expected to raise approximately $2.7 million. The offering includes warrants to purchase additional shares, aimed to boost working capital and fund the company’s commercialization initiatives. Roth Capital Partners is serving as the exclusive placement agent for this offering, which is anticipated to close on April 30, 2024, subject to customary conditions.
Read more →NUWENuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results Strengthens Its Foundation for Growth, Strong Pediatric Sales, Expanding Margins and Increases Number of New Hospital Accounts Minneapolis, MN
Nuwellis, Inc. reported a strong financial performance for the fourth quarter and full year ended December 31, 2023, highlighting record organic revenue, significant growth in pediatric sales, and an expanding number of hospital accounts. The CEO, Nestor Jaramillo, emphasized the successful execution of strategic initiatives and the impact of FDA approvals on the company’s portfolio. Despite challenges such as declining gross margins and increased net losses, Nuwellis remains optimistic about its growth trajectory in 2024, focusing on capitalizing on new medical opportunities. The company is implementing cost-saving measures to improve its financial position while pursuing additional product developments.
Read more →NUWENew Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload Early findings suggest Aquadex as a potential solution to safely and effectively remove fluid volume for
Nuwellis, Inc. has published new findings on the Aquadex SmartFlow system, revealing its potential benefits for end-stage liver disease patients experiencing fluid overload. The therapy, showcased in a case series involving 14 patients, can effectively remove excess fluid when conventional diuretics fail. This advancement may enhance patient mobility and prepare them for liver transplants more efficiently. Additionally, Aquadex is already approved for clinical use, requiring no further regulatory action, thus opening new market opportunities for the company.
Read more →NUWEFOR INVESTOR PURPOSES ONLY: NOT FOR PRODUCT PROMOTION 2024 Nuwellis, Inc. January 2024 Investor Presentation Aquadex FlexFlow and Aquadex SmartFlow are registered trademarks of Nuwellis, Inc. Aquadex is a trademark of Nu
Nuwellis, Inc. has provided an investor presentation outlining its focus on addressing fluid overload, which poses significant challenges in patient care and hospital resource management. The presentation notes the urgent market opportunity due to the high rates of fluid overload in critical care and heart failure patients. Nuwellis emphasizes its commitment to innovation but includes cautionary statements regarding the uncertainties and risks surrounding its future performance and market acceptance. Key data points highlight the serious implications of fluid overload for patient outcomes and hospital costs.
Read more →NUWENuwellis, Inc. Announces Third Quarter 2023 Financial Results Minneapolis, MN
Nuwellis, Inc. reported strong financial results for the third quarter of 2023, revealing a 17% increase in revenue compared to the previous year, primarily due to heightened adoption of their Aquadex Ultrafiltration System. The company also highlighted collaborations with SeaStar and DaVita, signaling potential future growth. However, despite the revenue growth, the gross margin decreased, and the company reported a net loss of $3.4 million for the quarter.
Read more →NUWENuwellis Announces Board of Directors Transition Nuwellis Announces Appointment of Dr. Archelle Georgiou, MD and Dave McDonald to its Board of Directors MINNEAPOLIS, November 1 , 2023 (GLOBE NEWSWIRE) - Nuwellis, Inc. (N
Nuwellis, Inc. has announced the appointment of Dr. Archelle Georgiou and Dave McDonald to its Board of Directors, effective November 1, 2023. Both bring extensive experience in their respective fields that will contribute to the company's growth and expansion strategies. Georgiou is renowned in healthcare policy and patient advocacy, while McDonald has a strong background in finance and investment banking. Additionally, the company acknowledged Jon Salveson's departure from the board after a decade of service, expressing gratitude for his contributions.
Read more →NUWENuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
Nuwellis, Inc. has priced a public offering of $2.25 million, consisting of 150,000 units of Series J Convertible Redeemable Preferred Stock and associated warrants. The units will be priced at $15.00 each and are expected to close on October 17, 2023. The funds raised will be allocated towards working capital and general corporate purposes, supporting the company's aim to transform the lives of patients suffering from fluid overload. The offering includes a three-year term for the preferred stock with a 5.0% dividend rate, paid in-kind.
Read more →NUWENuwellis Provides Regulatory Update on SeaStar Medical's Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption Minneapolis, MN
Nuwellis, Inc. has announced that its partner SeaStar Medical is likely to receive FDA approval for the Selective Cytopheretic Device (SCD) Pediatric for treating acute kidney injury in children. The approval is under a Humanitarian Device Exemption, with an Approvable Letter expected within a month that will outline conditions for formal marketing. This device aims to help children requiring continuous kidney replacement therapy, a population at significant risk of mortality.
Read more →NUWENUWELLIS ANNOUNCES PLAN FOR CFO TRANSITION Minneapolis
Nuwellis, Inc. is undergoing a CFO transition as Lynn Blake steps down to pursue broader career goals. She will assist the company until September 1, 2023, after which Rob Scott will be appointed as the new CFO. Scott, who has been with the company for a decade, is praised for his expertise in finance and understanding of the business. The leadership is optimistic about Scott's promotion and his role in driving future growth.
Read more →NUWENuwellis, Inc. Announces Second Quarter 2023 Financial Results Minneapolis, MN
Nuwellis, Inc. reported its second quarter 2023 financial results, indicating a rebound in business, particularly with a 72% increase in Pediatric sales compared to the first quarter. The company also saw a gross margin improvement attributed to a favorable product sales mix. However, revenue fell slightly to $2.1 million from $2.2 million in the prior year, and the net loss increased to $4.8 million. In a positive development, Nuwellis announced a partnership with DaVita to enhance the clinical adoption of its Aquadex ultrafiltration therapy.
Read more →NUWENUWELLIS INC. ANNOUNCES PILOT AGREEMENT WITH DAVITA INC. Supply Agreement to Pilot Ultrafiltration Therapy Services Offering in Select Markets MINNEAPOLIS
Nuwellis Inc. has entered a Supply and Collaboration Agreement with DaVita Inc. to pilot the Aquadex ultrafiltration therapy aimed at treating adult patients suffering from congestive heart failure and fluid overload. This program, launching by the end of Q3 2023, may increase the accessibility of ultrafiltration therapy to a broader patient demographic and could also reduce healthcare costs. The partnership will involve training, support for clinicians, and the possibility for DaVita to extend the agreement for additional years post-pilot if successful. Nuwellis is optimistic about this collaboration enhancing patient care and clinical adoption of their technology.
Read more →NUWENuwellis Announces the Appointment of Mike McCormick to its Board of Directors MINNEAPOLIS
Nuwellis, Inc., a medical technology company, announced the appointment of Mike McCormick to its Board of Directors. With over 25 years in the medical device industry, McCormick will also serve as Lead Independent Director and chair the Nominating and Corporate Governance Committee. His expertise, particularly as a former CEO of Osprey Medical, is expected to contribute significantly to Nuwellis' mission to help patients with fluid overload through innovative therapies. The company focuses on commercializing the Aquadex SmartFlow system for ultrafiltration therapy.
Read more →NUWENuwellis, Inc. Announces First Quarter 2023 Financial Results Minneapolis, MN
Nuwellis, Inc. announced its financial results for Q1 2023, reporting a revenue of $1.8 million, down from $1.9 million in the previous year. The company experienced an increased net loss of $6.5 million, attributed partly to greater expenses in selling and general administrative categories. However, the gross margin improved to 58.4%, and CEO Nestor Jaramillo highlighted growth in the heart failure segment and a commitment to making the Aquadex therapy a standard care solution. The company has cash reserves of $12.1 million and no debt.
Read more →NUWEMarch 2023 Investor Presentation 2023 Nuwellis, Inc Safe Harbor Statement Forward Looking Statement This presentation contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, a
Nuwellis, Inc. presented forward-looking statements regarding their strategic plans and growth outlook during their March 2023 investor presentation. The company is focusing on addressing fluid overload in patients, with an emphasis on expanding their Aquadex business, which they believe holds a significant market opportunity. The presentation outlined both the clinical and economic benefits of their products, reinforcement of their leadership team, and the innovative nature of their offerings aimed at improving patient care. However, they acknowledged various risks that could affect their projections and future performance.
Read more →NUWENuwellis, Inc. Announces Fourth Quarter and Full Year 2022 Financial Results Q4 Revenue Up 42%; Expansion of Clinical Evidence Sets Stage for 2023 Growth Minneapolis, MN
Nuwellis, Inc. reported a significant 42% revenue increase in Q4 2022 compared to the previous year, with total revenue reaching $2.3 million. The company emphasized its strategic initiatives for growth, including expanding its commercial team and leveraging clinical evidence for its Aquadex SmartFlow system. Despite the revenue increase, Nuwellis reported a net loss of $1.9 million for the quarter, along with rising operational expenses. The firm remains focused on establishing ultrafiltration therapy as the standard care for patients unresponsive to diuretics.
Read more →NUWENuwellis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results MINNEAPOLIS, January 9 , 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) ("Nuwellis" or the "Company"), a medical technology company f
Nuwellis, Inc. has reported preliminary unaudited revenue results for the fourth quarter and full year 2022, showing a revenue increase to approximately $2.3 million for Q4 and $8.5 million for the full year, marking a 42% and 8% increase respectively over the previous year. The growth was largely driven by the expansion of their sales team and successful penetration into new market segments beyond heart failure. Nuwellis is focused on establishing its Aquadex SmartFlow system as a key treatment option for patients experiencing fluid overload. However, the company also faces notable risks including commercialization execution challenges and market competition.
Read more →NUWESeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medical's Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI) Approximately 4,000 children in the U.S.
SeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medical's Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI) Approximately 4,000 children in the U.S. with AKI require Continuous Kidney Replacement Therapy (C
Read more →NUWENuwellis, Inc. Announces Compliance With Nasdaq Listing Requirements Minneapolis
Nuwellis, Inc. Announces Compliance With Nasdaq Listing Requirements Minneapolis, Dec. 27, 2022 (GLOBE NEWSWIRE) Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that on December 27, 2022
Read more →NUWENuwellis, Inc. Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum Minneapolis, Minn. /GLOBENEWSWIRE/
Nuwellis, Inc. Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum Minneapolis, Minn. /GLOBENEWSWIRE/December 8, 2022/ Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today a
Read more →NUWENuwellis, Inc. Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement Minneapolis, Minn. /GLOBENEWSWIRE/
Nuwellis, Inc. Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement Minneapolis, Minn. /GLOBENEWSWIRE/November 30, 2022/ Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company, announced today it received an extension of 180 calendar days from the Nasdaq
Read more →NUWENuwellis, Inc. Reports Third Quarter 2022 Financial Results Minneapolis, MN
Nuwellis, Inc. Reports Third Quarter 2022 Financial Results Minneapolis, MN, November 8, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for th
Read more →NUWENuwellis Announces Pricing of $9.6 Million Upsized Underwritten Public Offering
Nuwellis Announces Pricing of $9.6 Million Upsized Underwritten Public Offering MINNEAPOLIS, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) ("Nuwellis" or the "Company"), a commercial-stage company focused on transforming the lives of people with fluid overload,
Read more →NUWENUWELLIS ANNOUNCES DATA DEMONSTRATING STATISTICALLY SUPERIOR CLINICAL BENEFIT OF AQUADEX THERAPY IN REDUCING HEART FAILURE EVENTS AND MORTALITY AT THE 2022 HFSA MEETING Statistically Significant Reduction in CV Mortality
ANNOUNCES DATA DEMONSTRATING STATISTICALLY SUPERIOR CLINICAL BENEFIT OF AQUADEX THERAPY IN REDUCING HEART FAILURE EVENTS AND MORTALITY AT THE 2022 HFSA MEETING Significant Reduction in CV Mortality and HF Rehospitalizations as Compared to IV Diuretics at 30 and 90 Days MINNEAPO
Read more →NUWENUWELLIS ANNOUNCES THE ACTIVATION OF NEW SITES FOR ITS PIVOTAL REVERSE-HF TRIAL REVERSE-HF will evaluate ultrafiltration therapy in comparison to IV diuretics to treat heart failure patients with fluid overload MINNEAPOL
NUWELLIS ANNOUNCES THE ACTIVATION OF NEW SITES FOR ITS PIVOTAL REVERSE-HF TRIAL REVERSE-HF will evaluate ultrafiltration therapy in comparison to IV diuretics to treat heart failure patients with fluid MINNEAPOLIS, September 27, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq:
Read more →NUWENuwellis, Inc. Announces Second Quarter 2022 Financial Results Minneapolis, MN
Nuwellis, Inc. Announces Second Quarter 2022 Financial Results Minneapolis, MN, August 9, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the second quarter ended June 30, 2022, which included the following highlights: "I am very happy wi
Read more →NUWENuwellis, Inc. Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum Minneapolis, Minn. /GLOBALNEWSWIRE/
Nuwellis, Inc. Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum Minneapolis, Minn. /GLOBALNEWSWIRE/May 17, 2022/ Nuwellis, Inc. (NASDAQ: NUWE), today announced that the Company's 2022 Annual Meeting of Stockholders, on May 17, 2022 at 2:00 p.m., was
Read more →NUWENuwellis, Inc. Announces First Quarter 2022 Financial Results Minneapolis, MN
Nuwellis, Inc. Announces First Quarter 2022 Financial Results Minneapolis, MN, May 10, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the first quarter ended March 31, 2022, which included the following highlights: "I am very pleased wit
Read more →NUWENuwellis, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results Minneapolis, MN
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results Minneapolis, MN, March 1, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the fourth quarter and full year ended December 31, 2021, which included the following h
Read more →NUWENuwellis, Inc. Announces Third Quarter 2021 Financial Results Minneapolis, MN
Nuwellis, Inc. Announces Third Quarter 2021 Financial Results Minneapolis, MN, November 9, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the third quarter ended September 30, 2021, which included the following highlights: "Although the
Read more →NUWENuwellis, Inc. Announces Pricing of $8.7 Million Underwritten Public Offering of Common Stock
Nuwellis, Inc. Announces Pricing of $8.7 Million Underwritten Public Offering of Common Stock EDEN PRAIRIE, Minn., September 15, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) (the "Company") announced today the pricing of an underwritten public offering of 3,483,120 shar
Read more →NUWES e p t e m b e r 2 0 2 1 FOR INVESTOR PURPOSES ONLY: NOT FOR PRODUCT PROMOTION 2021 Nuwellis, Inc. 1 Forward Looking StatementThis presentation contains forward looking statements within the meaning of Section 27A of th
S e p t e m b e r 2 0 2 1 FOR INVESTOR PURPOSES ONLY: NOT FOR PRODUCT PROMOTION 2021 Forward Looking StatementThis presentation contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and
Read more →NUWENuwellis, Inc. Announces 35 Percent Increase in Revenue for Second Quarter 2021 Over Previous Year and Provides Company Update Eden Prairie, MN
Nuwellis, Inc. Announces 35 Percent Increase in Revenue for Second Quarter 2021 Over Previous Year and Provides Company Update Eden Prairie, MN, August 10, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the second quarter ended June 30, 20
Read more →NUWENuwellis Announces New Appointments to Leadership Team George Montague to serve as Chief Financial Officer and Neil P. Ayotte, to serve as General Counsel and Chief Compliance Officer.
Nuwellis Announces New Appointments to Leadership Team George Montague to serve as Chief Financial Officer and Neil P. Ayotte, to serve as General Counsel and Chief Compliance Officer. EDEN PRAIRIE, Minn., June 22, 2021 (GLOBE NEWSWIRE) - Continuing its dynamic growth in suppor
Read more →NUWEQ1-2021 Earnings Release v8 Nuwellis, Inc. Announces 18 Percent Increase in Revenue for First Quarter 2021 Over Previous Year and Provides Company Update Eden Prairie, MN
Q1-2021 Earnings Release v8 Nuwellis, Inc. Announces 18 Percent Increase in Revenue for First Quarter 2021 Over Previous Year and Provides Company Update Eden Prairie, MN: May 11, 2021: (GLOBE NEWSWIRE) Nuwellis, Inc. (Nasdaq: NUWE) (previously CHF Solutions, Inc.) announced to
Read more →NUWECHF Shifts Commercial Focus, Changes Name to Nuwellis The new name reflects the company's commitment to pediatric, critical care, and chronic heart failure
CHF Shifts Commercial Focus, Changes Name to Nuwellis The new name reflects the company's commitment to pediatric, critical care, and chronic heart failure EDEN PRAIRIE, MN, April 27, 2021 (GLOBE NEWSWIRE) - Company names are reflective of the services provided to its customers
Read more →NUWECHF Solutions, Inc. Announces Pricing of $18.1 Million Underwritten Public Offering of Common Stock
CHF Solutions, Inc. Announces Pricing of $18.1 Million Underwritten Public Offering of Common Stock EDEN PRAIRIE, Minn., March 17, 2021 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) (the "Company") today announced the pricing of an underwritten public offering of 3,300,7
Read more →NUWECHF Solutions, Inc. Announces 49.5 Percent Increase in Revenue for Fourth Quarter 2020 and Provides Company Update Eden Prairie, MN
CHF Solutions, Inc. Announces 49.5 Percent Increase in Revenue for Fourth Quarter 2020 and Provides Company Update Eden Prairie, MN: March 2, 2021: (GLOBE NEWSWIRE) CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the fourth quarter ended December 31, 2020. "C
Read more →NUWECHF Solutions Appoints Nestor Jaramillo, Jr. as President and Chief Executive Officer
CHF Solutions Appoints Nestor Jaramillo, Jr. as President and Chief Executive Officer EDEN PRAIRIE, MN, January 19, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today a
Read more →NUWECHF Solutions, Inc. Announces 52 Percent Increase in Revenue for Third Quarter 2020 and Provides Company Update Eden Prairie, MN
CHF Solutions, Inc. Announces 52 Percent Increase in Revenue for Third Quarter 2020 and Provides Company Update Eden Prairie, MN: November 10, 2020: (GLOBE NEWSWIRE) CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the third quarter ended September 30, 2020. "
Read more →NUWECHF Solutions Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement
CHF Solutions Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement EDEN PRAIRIE, Minn., September 1, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, ann
Read more →NUWECHF Solutions, Inc. Announces Pricing of $12.5 Million Underwritten Public Offering
CHF Solutions, Inc. Announces Pricing of $12.5 Million Underwritten Public Offering EDEN PRAIRIE, Minn., August 19, 2020 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS), a medical device company dedicated to improving the lives of patients suffering from fluid overload, to
Read more →NUWECHF Solutions, Inc. Announces 14 Percent Increase in Revenue for Second Quarter 2020 Over Previous Quarter and Provides Company Update Eden Prairie, MN
CHF Solutions, Inc. Announces 14 Percent Increase in Revenue for Second Quarter 2020 Over Previous Quarter and Provides Company Update Eden Prairie, MN: August 4, 2020: (GLOBE NEWSWIRE) CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the second quarter ended
Read more →NUWECHF Solutions promotes Nestor Jaramillo, Jr. to President and Chief Operating Officer
CHF Solutions promotes Nestor Jaramillo, Jr. to President and Chief Operating Officer EDEN PRAIRIE, Minn., June 25, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to improving the lives of patients suffering from fluid overload, today a
Read more →NUWECHF Solutions, Inc. Announces Adjournment of Annual Meeting of Stockholders Scheduled to Reconvene
CHF Solutions, Inc. Announces Adjournment of Annual Meeting of Stockholders Scheduled to Reconvene June 19, 2020 Company Strongly Encourages Stockholders to Vote EDEN PRAIRIE, MN, May 22, 2020 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) ("CHF Solutions") today announ
Read more →NUWECHF Solutions, Inc. Announces 34 Percent Increase in Revenue for First Quarter 2020 Over Previous Year and Provides Company Update Eden Prairie, MN
CHF Solutions, Inc. Announces 34 Percent Increase in Revenue for First Quarter 2020 Over Previous Year and Provides Company Update Eden Prairie, MN: May 12, 2020: (GLOBE NEWSWIRE) CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the first quarter ended March 31
Read more →NUWECHF Solutions, Inc. Announces Registered Direct Offering Priced At-the-Market
CHF Solutions, Inc. Announces Registered Direct Offering Priced At-the-Market EDEN PRAIRIE, MN, May 1, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (CHFS) today announced the pricing of a registered direct offering of 3,597,880 shares of its common stock at a price of $0.4725 per shar
Read more →NUWECHF Solutions, Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market
CHF Solutions, Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market EDEN PRAIRIE, MN, March 30, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the pricing of a registered direct offering of 5,130,228 shares of its common stock at a pr
Read more →NUWECHF Solutions, Inc. Announces Pricing of Registered Direct Offering
CHF Solutions, Inc. Announces Pricing of Registered Direct Offering EDEN PRAIRIE, MN, March 20, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the pricing of a registered direct offering of 4,161,392 shares of its common stock at a price to the public of
Read more →NUWECHF Solutions, Inc. Announces Fourth Quarter Financial Results and Provides Company Update Eden Prairie, MN
CHF Solutions, Inc. Announces Fourth Quarter Financial Results and Provides Company Update Eden Prairie, MN: March 3, 2020: (GLOBE NEWSWIRE) CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the fourth quarter and year ended December 31, 2019, which included the
Read more →NUWECHF Solutions, Inc. Announces Pricing of $8.4 Million Underwritten Public Offering
CHF Solutions, Inc. Announces Pricing of $8.4 Million Underwritten Public Offering EDEN PRAIRIE, Minn., Jan. 24, 2020 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) today announced the pricing of an underwritten public offering of units for gross proceeds of approximatel
Read more →NUWECHF Solutions, Inc. Announces Third Quarter Financial Results and Provides Company Update Eden Prairie, Minn.
CHF Solutions, Inc. Announces Third Quarter Financial Results and Provides Company Update Eden Prairie, Minn., November 5, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS), a medical device company focused on developing, manufacturing and commercializing a clinically
Read more →NUWECorporate Presentation (NASDAQ: CHFS)
Corporate Presentation (NASDAQ: CHFS)September 24, 2019 For Investor Purposes Only: Not For Product This presentation contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange A
Read more →NUWECHF Solutions, Inc. Appoints World-Renowned Heart Failure Cardiologist, Maria Rosa Costanzo, M.D. to Company's Board of Directors
CHF Solutions, Inc. Appoints World-Renowned Heart Failure Cardiologist, Maria Rosa Costanzo, M.D. to Company's Board of Directors EDEN PRAIRIE, Minn., Sept. 04, 2019 (GLOBE NEWSWIRE) - CHF Solutions, Inc. (NASDAQ:CHFS) today announced that Maria Rosa Costanzo, M.D. has been appo
Read more →NUWECHF Solutions, Inc. Announces 53 Percent Increase in Revenues for Second Quarter 2019 Over Previous Year and 38 Percent Increase from Q1 2019 Eden Prairie, Minn.
CHF Solutions, Inc. Announces 53 Percent Increase in Revenues for Second Quarter 2019 Over Previous Year and 38 Percent Increase from Q1 2019 Eden Prairie, Minn., August 6, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS), a medical device company focused on developin
Read more →NUWECHF Solutions, Inc. Announces 17 Percent Increase in Revenues for First Quarter 2019 Over Previous Year and Provides Company Update Eden Prairie, Minn.
CHF Solutions, Inc. Announces 17 Percent Increase in Revenues for First Quarter 2019 Over Previous Year and Provides Company Update Eden Prairie, Minn., May 7, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the first quarter ended Mar
Read more →NUWECHF Solutions, Inc. Announces Pricing of $10.8 Million Underwritten Public Offering Eden Prairie, Minn /GLOBE NEWSWIRE /
CHF Solutions, Inc. Announces Pricing of $10.8 Million Underwritten Public Offering Eden Prairie, Minn /GLOBE NEWSWIRE / March 8, 2019 / CHF Solutions, Inc. (NASDAQ:CHFS) today announced the pricing of an underwritten public offering of units for gross proceeds of approximately
Read more →NUWECHF Solutions, Inc. Announces 80% Revenue Growth for its Fourth Quarter and Provides Company Update Eden Prairie, MN
CHF Solutions, Inc. Announces 80% Revenue Growth for its Fourth Quarter and Provides Company Update Eden Prairie, MN: February 20, 2019: (GLOBE NEWSWIRE) CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the fourth quarter and year ended December 31, 2018, whic
Read more →NUWECHF Solutions, Inc. Announces 42% Revenue Growth for its Third Quarter and Provides Company Update Eden Prairie, MN
CHF Solutions, Inc. Announces 42% Revenue Growth for its Third Quarter and Provides Company Update Eden Prairie, MN: November 6, 2018: CHF Solutions, Inc. (NASDAQ: CHFS) announced today its third quarter results for the period ended September 30, 2018. Highlights include: "We
Read more →NUWECHF Solutions, Inc. Announces 27% Revenue Growth for its Second Quarter and Provides Company Update Eden Prairie, MN
CHF Solutions, Inc. Announces 27% Revenue Growth for its Second Quarter and Provides Company Update Eden Prairie, MN: August 7, 2018: CHF Solutions, Inc. (NASDAQ: CHFS) announced today its second quarter results for the period ended June 30, 2018. Highlights include: "We have c
Read more →NUWEDepartment of Veterans Affairs Awards a $6.5 million Blanket Purchase Agreement to CHF Solutions to Supply Aquadex FlexFlow System for Outpatient Services in Tampa, Fla.
Department of Veterans Affairs Awards a $6.5 million Blanket Purchase Agreement to CHF Solutions to Supply Aquadex FlexFlow System for Outpatient Services in Tampa, Fla. EDEN PRAIRE, MN, July 25, 2018 (GLOBE NEWSWIRE) - As previously disclosed on its website, FedBizOps.gov, the
Read more →NUWECHF Solutions, Inc. Announces Closing of Common Stock Offering
CHF Solutions, Inc. Announces Closing of Common Stock Offering EDEN PRAIRIE, Minn., July 3, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) today announced the closing of its previously-announced underwritten public offering of 2,547,169 shares of its common stock at
Read more →NUWECHF Solutions, Inc. Announces Pricing of Common Stock Offering
CHF Solutions, Inc. Announces Pricing of Common Stock Offering EDEN PRAIRIE, Minn., June 29, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) today announced the pricing of an underwritten public offering of 2,214,930 shares of its common stock at a price to the public
Read more →NUWECHF Solutions, Inc. Announces 25 Percent Increase in Revenues for First Quarter 2018 Over Previous Quarter and Provides Company Update Eden Prairie, Minn.
CHF Solutions, Inc. Announces 25 Percent Increase in Revenues for First Quarter 2018 Over Previous Quarter and Provides Company Update Eden Prairie, Minn., May 8, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the first quarter ended
Read more →NUWECHF Solutions, Inc. Announces 11.4 Percent Revenue Growth for its Fourth Quarter and Provides Company Update Eden Prairie, MN
CHF Solutions, Inc. Announces 11.4 Percent Revenue Growth for its Fourth Quarter and Provides Company Update Eden Prairie, MN: March 20, 2018: (GLOBE NEWSWIRE) CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the fourth quarter and year ended December 31, 2017,
Read more →NUWECHF Solutions, Inc.
CHF Solutions, Inc. Announces Closing of $18.0 Million Underwritten Public Offering Eden Prairie, MN: November 27, 2017: CHF Solutions, Inc. (NASDAQ: CHFS) announced today the closing of an underwritten public offering of Series F convertible preferred stock, together with warra
Read more →NUWECHF Solutions, Inc. Announces 21% Revenue Growth for its Third Quarter, 2017 and Provides Company Update Eden Prairie, MN
CHF Solutions, Inc. Announces 21% Revenue Growth for its Third Quarter, 2017 and Provides Company Update Eden Prairie, MN: October 31, 2017: CHF Solutions, Inc. (NASDAQ: CHFS) announced today its third quarter 2017 results, for the period ending September 30, 2017, which include
Read more →NUWECHF Solutions Announces 1 for 20 Reverse Split Ratio
CHF Solutions Announces 1 for 20 Reverse Split Ratio EDEN PRAIRIE, Minn., October 12, 2017 (GLOBE NEWSWIRE) - CHF Solutions, Inc. (NASDAQ:CHFS) announced today a 1-for-20 reverse split of its common stock, effective at 5:00 pm Eastern time today. Beginning tomorrow, October 13,
Read more →NUWECHF Solutions, Inc. Announces 18% Revenue Growth for its Second Quarter and Provides Company Update Eden Prairie, MN
CHF Solutions, Inc. Announces 18% Revenue Growth for its Second Quarter and Provides Company Update Eden Prairie, MN: August 8, 2017: CHF Solutions, Inc. (NASDAQ: CHFS) announced today its second quarter results for the period ending June 30, 2017, which included the following h
Read more →NUWESunshine Heart Announces Company Name Change to CHF Solutions, Inc. and New NASDAQ Ticker Symbol to Reflect New Commercial Focus
Sunshine Heart Announces Company Name Change to CHF Solutions, Inc. and New NASDAQ Ticker Symbol to Reflect New Commercial Focus EDEN PRAIRIE, Minn., May 23, 2017 (GLOBE NEWSWIRE) Sunshine Heart, Inc. (NASDAQ:SSH), an early-stage medical device company focused on the commerciali
Read more →NUWESunshine Heart Announces First Quarter 2017 Financial Results and Provides Company Update Eden Prairie, MN
Sunshine Heart Announces First Quarter 2017 Financial Results and Provides Company Update Eden Prairie, MN: May 9, 2017: (GLOBE NEWSWIRE) Sunshine Heart, Inc. (NASDAQ: SSH) announced today its financial results for the first quarter ended March 31, 2017. The Company will host a
Read more →NUWESunshine Heart Announces Closing of $9.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option Eden Prairie, MN
Sunshine Heart Announces Closing of $9.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option Eden Prairie, MN: April 24, 2017: (GLOBE NEWSWIRE) Sunshine Heart, Inc. (NASDAQ: SSH) announced today the closing of an underwritten public offering of units
Read more →NUWESunshine Heart Receives Nasdaq Listing Extension
Sunshine Heart Receives Nasdaq Listing Extension EDEN PRAIRIE, Minn., March 29, 2017 (GLOBE NEWSWIRE) Sunshine Heart, Inc. (NASDAQ:SSH) announced today that the Nasdaq Hearings Panel (the Panel ) has granted the Company s request for continued listing on Nasdaq pursuant to an ex
Read more →NUWESunshine Heart Announces Fourth Quarter 2016 Financial Results and Provides Company Update Eden Prairie, MN
Sunshine Heart Announces Fourth Quarter 2016 Financial Results and Provides Company Update Eden Prairie, MN: March 2, 2017: (GLOBE NEWSWIRE) Sunshine Heart, Inc. (NASDAQ: SSH) announced today its financial results for the fourth quarter ended December 31, 2016. The Company will
Read more →NUWESunshine Heart Compliant with Nasdaq Bid Price Requirement
Sunshine Heart Compliant with Nasdaq Bid Price Requirement EDEN PRAIRIE, Minn., Feb. 10, 2017 (GLOBE NEWSWIRE) Sunshine Heart, Inc. (NASDAQ: SSH) announced today that on February 9, 2017, the Company received formal notice from The NASDAQ Stock Market LLC indicating that the Com
Read more →NUWESunshine Heart Appoints Steve Brandt and Matthew E. Likens to Board of Directors Eden Prairie, MN
Sunshine Heart Appoints Steve Brandt and Matthew E. Likens to Board of Directors Eden Prairie, MN: February 3, 2017: Sunshine Heart, Inc. (NASDAQ: SSH; ASX: SHC) today announced that Steven F. Brandt and Matthew E. Likens have been appointed to the Company s Board of Directors.
Read more →NUWESunshine Heart Announces 1-for-30 Reverse Stock Split Eden Prairie, MN
Sunshine Heart Announces 1-for-30 Reverse Stock Split Eden Prairie, MN: January 12, 2017: (GLOBE NEWSWIRE) Sunshine Heart, Inc. today announced a 1-for-30 reverse split of its common stock, effective at 5:00 pm Eastern time today. Beginning tomorrow, January 13, 2017, the Compan
Read more →NUWESunshine Heart Urges Stockholders to Vote for Proposals at January 9 Special Stockholder Meeting Eden Prairie, MN
Sunshine Heart Urges Stockholders to Vote for Proposals at January 9 Special Stockholder Meeting Eden Prairie, MN: December 21, 2016: Sunshine Heart, Inc. (NASDAQ: SSH) ( Sunshine Heart or the Company ) today urged stockholders of record at the close of business on December 2, 2
Read more →NUWESunshine Heart Announces Receipt of Nasdaq Extension to Comply with Listing Requirements Eden Prairie, MN
Sunshine Heart Announces Receipt of Nasdaq Extension to Comply with Listing Requirements Eden Prairie, MN: November 22, 2016: (GLOBE NEWSWIRE) Sunshine Heart, Inc. (NASDAQ: SSH) today announced that on November 21, 2016 it received a letter from the Nasdaq Office of General Coun
Read more →NUWESunshine Heart Announces Receipt of Additional Nasdaq Staff Determination Eden Prairie, MN
Sunshine Heart Announces Receipt of Additional Nasdaq Staff Determination Eden Prairie, MN: November 17, 2016: (GLOBE NEWSWIRE) Sunshine Heart, Inc. today announced that on November 11, 2016, the Company received a letter from the Nasdaq Listing Qualifications Staff indicating t
Read more →NUWESunshine Heart Announces Third Quarter 2016 Financial Results and Provides Company Update Eden Prairie, MN
Sunshine Heart Announces Third Quarter 2016 Financial Results and Provides Company Update Eden Prairie, MN: November 8, 2016: (GLOBE NEWSWIRE) Sunshine Heart, Inc. (NASDAQ: SSH) announced today its financial results for the third quarter ended September 30, 2016. The Company wil
Read more →NUWESunshine Heart Announces Exchange and $3.8 Million Offering Eden Prairie, MN
Sunshine Heart Announces Exchange and $3.8 Million Offering Eden Prairie, MN: October 31, 2016: (GLOBE NEWSWIRE) Sunshine Heart, Inc. (Nasdaq: SSH) ( Sunshine Heart or the Company ) today announced that it has entered into a definitive agreement with a healthcare dedicated insti
Read more →NUWESunshine Heart Announces Strategic Realignment Eden Prairie, MN
Sunshine Heart Announces Strategic Realignment Eden Prairie, MN: September 29, 2016: (GLOBE NEWSWIRE) Sunshine Heart, Inc. (NASDAQ: SSH) today announced that it is implementing a strategic realignment of its near term strategy to fully focus the Company s resources on its recent
Read more →NUWESunshine Heart Announces Receipt of Nasdaq Staff Determination; To Request Hearing Eden Prairie, MN
Sunshine Heart Announces Receipt of Nasdaq Staff Determination; Eden Prairie, MN: September 23, 2016: (GLOBE NEWSWIRE) Sunshine Heart, Inc. (NASDAQ: SSH) today announced that on September 21, 2016, it received a letter from the Nasdaq Listing Qualifications Staff indicating that
Read more →NUWECompany Update investMNt Conference Minneapolis, MN
Company Update investMNt Conference Minneapolis, MN August 24, 2016 FRM-04558-D 2016 Sunshine Heart, Inc. Forward Looking Statement This presentation contains forward-looking statements. All forward-looking statements are management s present expectations of future events and ar
Read more →NUWESunshine Heart Announces Second Quarter 2016 Financial Results and Provides Company Update Eden Prairie, MN
Sunshine Heart Announces Second Quarter 2016 Financial Results and Provides Company Update Eden Prairie, MN: August 9, 2016: (GLOBE NEWSWIRE) Sunshine Heart, Inc. (NASDAQ: SSH) announced today its financial results for the second quarter ended June 30, 2016. The Company will hos
Read more →NUWESunshine Heart Announces Strategic Acquisition of Aquadex Product Line from Baxter and a new credit facility with Silicon Valley Bank Eden Prairie, MN
Sunshine Heart Announces Strategic Acquisition of Aquadex Product Line from Baxter and a new credit facility with Silicon Valley Bank Eden Prairie, MN: August 8, 2016: (GLOBE NEWSWIRE) Sunshine Heart, Inc. (NASDAQ: SSH) announced it has acquired the Aquadex product line from an
Read more →NUWESunshine Heart Announces $3.5 Million Offering
Sunshine Heart Announces $3.5 Million Offering EDEN PRAIRIE, Minn., July 21, 2016 Sunshine Heart, Inc. (Nasdaq: SSH) ( Sunshine Heart or the Company ), today announced that it has entered into a definitive agreement with a single investor for an offering of shares of convertible
Read more →NUWESunshine Heart Announces Clinical Update and Product Development Strategy
Sunshine Heart Announces Clinical Update and Product Development Strategy EDEN PRAIRIE, Minn., July 11, 2016 (GLOBE NEWSWIRE) Sunshine Heart, Inc. (NASDAQ:SSH) announced today an update to its clinical strategy that could benefit an underserved population of patients with Class
Read more →NUWESunshine Heart Announces First Quarter 2016 Financial Results and Provides Company Update Eden Prairie, MN
Sunshine Heart Announces First Quarter 2016 Financial Results and Provides Company Update Eden Prairie, MN: May 3, 2016: (GLOBE NEWSWIRE) Sunshine Heart, Inc. (NASDAQ: SSH) announced today its financial results and provided a company update for the first quarter ended March 31,
Read more →NUWEThis image cannot currently be display ed. Corporate Update March 2016 www.sunshineheart.com TThhisis imimagagee ccaannnnoott ccuurrrrenenttllyy bbee didissppllaayy eed.d. Forward Looking Statement This presentation cont
This image cannot currently be display ed. Corporate Update March 2016 www.sunshineheart.com TThhisis imimagagee ccaannnnoott ccuurrrrenenttllyy bbee didissppllaayy eed.d. Forward Looking Statement This presentation contains forward-looking statements. All forward-looking statem
Read more →NUWESunshine Heart Announces Fourth Quarter and Twelve Months 2015 Financial Results and Provides Corporate Update Eden Prairie, MN
Sunshine Heart Announces Fourth Quarter and Twelve Months 2015 Financial Results and Provides Corporate Update Eden Prairie, MN: March 3, 2016: (GLOBE NEWSWIRE) Sunshine Heart, Inc. (NASDAQ: SSH) announced today its financial results and provided a corporate update for the fourt
Read more →NUWESunshine Heart Announces the Appointment of John Erb as its Chief Executive Officer
Sunshine Heart Announces the Appointment of John Erb as its Chief Executive Officer EDEN PRAIRIE, MN, Mar. 2, 2016 (GLOBE NEWSWIRE) Sunshine Heart, Inc. (Nasdaq:SSH) announced today the appointment of John Erb as its fulltime Chief Executive Officer (CEO) and President, effectiv
Read more →NUWEFIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This First Amendment to Loan and Security Agreement (this Amendment ) is entered into this 8 th day of December, 2015 by and between SILICON VALLEY BANK ( Bank ) and SUNSHIN
LOAN AND SECURITY AGREEMENT This First Amendment to Loan and Security Agreement (this Amendment ) is entered into this 8th day of December, 2015 by and between SILICON VALLEY BANK ( Bank ) and SUNSHINE HEART, INC., a Delaware corporation ( Borrower ) whose address is 12988 Valle
Read more →NUWESEPARATION AND RELEASE AGREEMENT THIS SEPARATION AND RELEASE AGREEMENT (this Agreement ) is made as of
SEPARATION AND RELEASE AGREEMENT THIS SEPARATION AND RELEASE AGREEMENT (this Agreement ) is made as of November 30, 2015 by and between SUNSHINE HEART, INC., a Delaware corporation, whose address is 12988 Valley View Road, Eden Prairie, Minnesota 55344 (the Company ) and DAVID A
Read more →NUWESunshine Heart Announces Third Quarter 2015 Results and Provides Corporate Update Eden Prairie, MN
Sunshine Heart Announces Third Quarter 2015 Results and Provides Corporate Update Eden Prairie, MN: November 3, 2015: Sunshine Heart, Inc. (NASDAQ: SSH) announced today its financial results and provided a corporate update for the third quarter of 2015. The Company will host a c
Read more →NUWEHemodynamicsof C-Pulse:Aortic Counterpulsation and Beyond? www.sunshineheart.com Dimitrios Georgakopoulos, PhD CSO, Sunshine Heart Inc. FRM-04558-B Forward Looking Statement This presentation contains forward-looking sta
Hemodynamicsof C-Pulse:Aortic Counterpulsation and Beyond? www.sunshineheart.com Dimitrios Georgakopoulos, PhD CSO, Sunshine Heart Inc. FRM-04558-B Forward Looking Statement This presentation contains forward-looking statements. All forward-looking statements are management s pr
Read more →NUWESunshine Heart to Present Hemodynamic Data Supporting Mechanism of Action of the C-Pulse System at 2015 Transcatheter Cardiovascular Therapeutics Conference Eden Prairie, MN
Sunshine Heart to Present Hemodynamic Data Supporting Mechanism of Action of the C-Pulse System at 2015 Transcatheter Cardiovascular Therapeutics Conference Eden Prairie, MN: October 08, 2015: Sunshine Heart, Inc. (NASDAQ:SSH) announced today that its flagship C-Pulse Heart Assi
Read more →NUWESunshine Heart Announces FDA Approves Key Protocol Amendment for COUNTER HF US Pivotal Study for C-Pulse Heart Assist System Eden Prairie, MN
Sunshine Heart Announces FDA Approves Key Protocol Amendment for COUNTER HF US Pivotal Study for C-Pulse Heart Assist System Eden Prairie, MN: August 31, 2015: Sunshine Heart, Inc. (NASDAQ:SSH) is pleased to announce the US Food and Drug Administration (FDA) has approved an amen
Read more →NUWESunshine Heart Announces Second Quarter 2015 Results and Provides Corporate Update Eden Prairie, MN
Sunshine Heart Announces Second Quarter 2015 Results and Provides Corporate Update Eden Prairie, MN: August 4, 2015: Sunshine Heart, Inc. (NASDAQ: SSH) announced today its financial results and provided a corporate update for the second quarter of 2015. The Company will host a c
Read more →NUWESunshine Heart Provides Update on COUNTER HF US Pivotal Study for C-Pulse Heart Assist System Eden Prairie, MN
Sunshine Heart Provides Update on COUNTER HF US Pivotal Study for C-Pulse Heart Assist System Eden Prairie, MN: July 23, 2015: Sunshine Heart, Inc. (NASDAQ: SSH) announced today an update on its COUNTER HF US pivotal study for the C-Pulse Heart Assist System. COUNTER HF is a pr
Read more →NUWESunshine Heart Exercises $2 Million Milestone Advance from Silicon Valley Bank Eden Prairie, MN
Sunshine Heart Exercises $2 Million Milestone Advance from Silicon Valley Bank Eden Prairie, MN: June 29, 2015: Sunshine Heart, Inc. (NASDAQ:SSH) announced today that it has exercised the right to borrow an additional $2 million under its existing loan and security agreement wit
Read more →NUWESunshine Heart Announces FDA Approval to Resume Enrollment in COUNTER HF US Pivotal Study for C-Pulse Heart Assist System Eden Prairie, MN
Sunshine Heart Announces FDA Approval to Resume Enrollment in COUNTER HF US Pivotal Study for C-Pulse Heart Assist System Eden Prairie, MN: May 26, 2015: Sunshine Heart, Inc. (NASDAQ:SSH) is pleased to announce that the US Food and Drug Administration (FDA) has approved the resu
Read more →NUWESunshine Heart Announces First Quarter 2015 Results and Provides Corporate Update Eden Prairie, MN
Sunshine Heart Announces First Quarter 2015 Results and Provides Corporate Update Eden Prairie, MN: May 5, 2015: Sunshine Heart, Inc. (NASDAQ: SSH) announced today its financial results and provided a corporate update for the first quarter of 2015. To access the live webcast, p
Read more →NUWESunshine Heart Provides Update on U.S. Pivotal Study of C-Pulse Heart Assist System Eden Prairie, MN
Sunshine Heart Provides Update on U.S. Pivotal Study of C-Pulse Heart Assist System Eden Prairie, MN: April 16, 2015: Sunshine Heart, Inc. (NASDAQ:SSH) announced today that the U.S. Food and Drug Administration (FDA) has reviewed the Company s submission regarding the COUNTER HF
Read more →NUWESunshine Heart Announces Fourth Quarter and Twelve Months 2014 Financial Results and Provides Corporate Update Eden Prairie, MN
Sunshine Heart Announces Fourth Quarter and Twelve Months 2014 Financial Results and Provides Corporate Update Eden Prairie, MN: March 17, 2015: Sunshine Heart, Inc. (NASDAQ:SSH) today announced its financial results and provided a corporate update for the fourth quarter and ye
Read more →NUWESunshine Heart Receives FDA Approval for Interim Analysis of U.S. Pivotal Trial of C-Pulse Heart Assist System Eden Prairie, MN
Sunshine Heart Receives FDA Approval for Interim Analysis of U.S. Pivotal Trial of C-Pulse Heart Assist System Eden Prairie, MN: February 25, 2015: Sunshine Heart, Inc. (NASDAQ:SSH) today announced it has received unconditional approval from the FDA to conduct an interim analysi
Read more →NUWESunshine Heart, Inc. Secures up to $10 Million in Growth Capital from Silicon Valley Bank Eden Prairie, MN
Sunshine Heart, Inc. Secures up to $10 Million in Growth Capital from Silicon Valley Bank Eden Prairie, MN: February 19, 2015: Sunshine Heart, Inc. (NASDAQ: SSH) (the Company or Sunshine Heart ) today announced that it has entered into a loan and security agreement with Silicon
Read more →NUWESunshine Heart Provides Corporate Update Eden Prairie, MN
Sunshine Heart Provides Corporate Update Eden Prairie, MN: January 12, 2015: Sunshine Heart, Inc. (NASDAQ: SSH) today provided an update on the Company s U.S. Counter HF and European OPTIONS HF studies along with progress on its next generation, fully implantable C-Pulse Heart A
Read more →NUWESunshine Heart Provides Clarification Following Third Quarter 2014 Financial Results Conference Call Eden Prairie, MN
Sunshine Heart Provides Clarification Following Third Quarter 2014 Financial Results Conference Call Eden Prairie, MN: November 3, 2014: Sunshine Heart, Inc. (NASDAQ:SSH) today provided a clarification of information covered during its October 30, 2014 third quarter financial re
Read more →NUWESunshine Heart to Provide Clinical Updates from the North American Feasibility Study and OPTIONS HF European Post-Market Study at 2014 Transcatheter Cardiovascular Therapeutics (TCT) Conference
Sunshine Heart to Provide Clinical Updates from the North American Feasibility Study and OPTIONS HF European Post-Market Study at 2014 Transcatheter Cardiovascular Therapeutics (TCT) Conference EDEN PRAIRIE, Minn., September 16, 2014 (GLOBE NEWSWIRE) Sunshine Heart, Inc. (Nasd
Read more →NUWESunshine Heart to Provide Summary of Initial OPTIONS HF Data and Additional Clinical Updates at 2013 Transcatheter Cardiovascular Therapeutics Analyst Event Eden Prairie, MN
Sunshine Heart to Provide Summary of Initial OPTIONS HF Data and Additional Clinical Updates at 2013 Transcatheter Cardiovascular Therapeutics Analyst Event Eden Prairie, MN: October 29, 2013: Sunshine Heart, Inc. (NASDAQ: SSH) announced today that the initial C-Pulse System pat
Read more →NUWESunshine Heart, Inc. Prices $40.0 Million Public Offering of Common Shares Eden Prairie, MN
Sunshine Heart, Inc. Prices $40.0 Million Public Offering of Common Shares Eden Prairie, MN: September 19, 2013: Sunshine Heart, Inc. (NASDAQ: SSH) announced today the pricing of its previously announced offering of 3,810,000 shares of its common stock at a price to the public o
Read more →NUWESunshine Heart, Inc. Announces Proposed Public Offering of Common Shares Eden Prairie, MN
Sunshine Heart, Inc. Announces Proposed Public Offering of Common Shares Eden Prairie, MN: September 18, 2013: Sunshine Heart, Inc. (NASDAQ: SSH) announced today that it has commenced an underwritten public offering of its common stock pursuant to its effective shelf registratio
Read more →NUWESunshine Heart Adopts Stockholder Rights Plan Eden Prairie, MN: June X, 2013: Sunshine Heart, Inc. (NASDAQ: SSH) today announced that its Board of Directors adopted a stockholder rights plan (the Rights Plan or Plan ) an
Sunshine Heart Adopts Stockholder Rights Plan Eden Prairie, MN: June X, 2013: Sunshine Heart, Inc. (NASDAQ: SSH) today announced that its Board of Directors adopted a stockholder rights plan (the Rights Plan or Plan ) and declared a dividend distribution of one right ( Right ) f
Read more →NUWESunshine Heart, Inc. Prices $13.1 Million Public Offering of Common Shares Eden Prairie, MN and Sydney, Australia
Sunshine Heart, Inc. Prices $13.1 Million Public Offering of Common Shares Eden Prairie, MN and Sydney, Australia: April 11, 2013: Sunshine Heart, Inc. (NASDAQ: SSH /ASX: SHC) announced today the pricing of its previously announced offering of 2,500,000 shares of its common stoc
Read more →NUWESunshine Heart, Inc. Announces Proposed Public Offering of Common Shares Eden Prairie, MN and Sydney, Australia
Sunshine Heart, Inc. Announces Proposed Public Offering of Common Shares Eden Prairie, MN and Sydney, Australia: April 10, 2013: Sunshine Heart, Inc. (NASDAQ: SSH /ASX: SHC) announced that it has commenced an underwritten public offering of its common stock pursuant to its effec
Read more →NUWEASX Announcement Sunshine Heart Announces Donal O Dwyer Will Retire From Board of Directors Eden Prairie, MN and Sydney, Australia: 2 April 2013: Sunshine Heart, Inc. (NASDAQ: SSH; ASX: SHC) today announced that Donal O
Sunshine Heart Announces Donal O Dwyer Will Retire From Board of Directors Eden Prairie, MN and Sydney, Australia: 2 April 2013: Sunshine Heart, Inc. (NASDAQ: SSH; ASX: SHC) today announced that Donal O Dwyer will retire from the Board of Directors following the completion of hi
Read more →NUWESunshine Heart Appoints Jon Salveson to Board of Directors Eden Prairie, MN and Sydney, Australia
Sunshine Heart Appoints Jon Salveson to Board of Directors Eden Prairie, MN and Sydney, Australia: March 13, 2013: Sunshine Heart, Inc. (NASDAQ: SSH; ASX: SHC) today announced that Jon W. Salveson has been appointed to the Company s Board of Directors. Mr. Salveson is the Vice C
Read more →NUWEASX Announcement ASX Grants Conditional Approval to Delist Eden Prairie, MN and Sydney, Australia: 5 February 2013 Sunshine Heart, Inc. (NASDAQ: SSH; ASX: SHC) ( Sunshine Heart ) today announced that it has received cond
ASX Grants Conditional Approval to Delist Eden Prairie, MN and Sydney, Australia: 5 February 2013 Sunshine Heart, Inc. (NASDAQ: SSH; ASX: SHC) (Sunshine Heart) today announced that it has received conditional approval from the ASX to delist from the official list of the ASX unde
Read more →NUWESunshine Heart Appoints Warren Watson to Board of Directors Seasoned Leader in Cardiology Joins as Director Replacing William Peters Eden Prairie, MN and Sydney, Australia
Sunshine Heart Appoints Warren Watson to Board of Directors Seasoned Leader in Cardiology Joins as Director Replacing William Peters Eden Prairie, MN and Sydney, Australia: January 30, 2013: Sunshine Heart, Inc. (NASDAQ: SSH; ASX: SHC) today announced that Warren Watson has bee
Read more →NUWESunshine Heart Enters Into a $25 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC Eden Prairie, MN and Sydney, Australia
Sunshine Heart Enters Into a $25 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC Eden Prairie, MN and Sydney, Australia; January 15, 2013: Sunshine Heart, Inc. (NASDAQ:SSH; ASX:SHC), a global medical device company focused on innovative technologies for mo
Read more →NUWESunshine Heart Provides Clinical Update Eden Prairie, MN and Sydney, Australia
Sunshine Heart Provides Clinical Update Eden Prairie, MN and Sydney, Australia: January 7, 2013: Sunshine Heart, Inc. (NASDAQ: SSH; ASX: SHC) today provided the following clinical update on the progress of the C-Pulse Heart Assist System. United States (U.S.) Pivotal Trial Sev
Read more →NUWESunshine Heart Announces Resignation of Director Eden Prairie, MN and Sydney, Australia: 13 November, 2012 : Sunshine Heart, Inc. (NASDAQ: SSH; ASX: SHC), a global medical device company focused on innovative technologie
Sunshine Heart Announces Resignation of Director Eden Prairie, MN and Sydney, Australia: 13 November, 2012: Sunshine Heart, Inc. (NASDAQ: SSH; ASX: SHC), a global medical device company focused on innovative technologies for moderate heart failure, today announced that Mark Harv
Read more →NUWESunshine Heart Announces 3Q12 Financial Results Key Regulatory and Financing Milestones Achieved Eden Prairie, MN and Sydney, Australia
Sunshine Heart Announces 3Q12 Financial Results Key Regulatory and Financing Milestones Achieved Eden Prairie, MN and Sydney, Australia: November 8, 2012: Sunshine Heart, Inc. (NASDAQ: SSH; ASX: SHC) today announced financial results for the third quarter and nine months ended
Read more →Competitive Position
How NUWE ranks across every disease it competes inCompetitive Position is a premium feature
See how NUWE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial